OBJECTIVE: To investigate how extracorporal cholesterol lowering therapy affects circulating leptin levels in patients with ravenous hunger after treatment and permanent weight gain. DESIGN: A case report. SUBJECT: 51 y old caucasian male patient with moderate chronic renal failure. MEASUREMENTS: Serum Leptin concentration (RIA, Linco Research Inc, St. Louis, MO, USA), total cholesterol, low density lipoprotein cholesterol, blood glucose levels, calorie intake by food records. RESULTS: During treatment total cholesterol was reduced by 50%. Serum Leptin levels showed a 42% reduction at the end of treatment, that by far exceeds the physiological diurnal variation. Calorie intake was signi®cantly increased on days of treatment. CONCLUSION: We conclude that this arti®cial reduction in circulating leptin plays an important role in the pathogenesis of ravenous hunger and weight gain under extracorporal cholesterol lowering therapy in this case.
Leptin, the protein of the ob gene, is thought to be involved in the regulation of body weight by transmission of a`lipostatic' signal from fat stores to the central nervous system resulting in appetite suppression and increased thermogenesis. 1 As a consequence, leptin de®ciency has been shown to result in excessive obesity in both mice 1 and men. 2 Hereby we report on a 51 y old caucasian male patient with moderate chronic renal failure (serum creatinine of 3.1 mgadl) on a chronic extracorporal cholesterol lowering therapy due to drug resistant hyperlipidaemia for 14 months. Therapy was performed with Cascade¯o AC-1770 (Asahi Medical Co. Ltd, Frankfurt, Germany) once a week for 3 h. Since the onset of therapy the patient showed permanent weight gain of 18 kg up to an actual body weight of 96 kg (body mass index 32.7 kgam 2 ). Assessment of body composition by bio impedance (BODY4, Data input, Frankfurt, Germany) revealed a fat mass of 34.3 kg corresponding to 35.7% of total body weight. Additionally the patient complained of ravenous hunger with excessive food intake after treatment. Food records, performed periodically, revealed a signi®cant increase of energy intake on days of treatment (3178 kcal AE 37 vs 2053 kcal AE 208 on days without treatment). Diet was quanti®ed by computed analysis (EWP, dato Denkwerkzeuge, Vienna, Austria).
The hypothesis of our investigation was to test the possibility that, additionally to lipid particles, plasma leptin might be eliminated during apheresis therapy. Therefore leptin concentrations were measured before, during and after therapy and 2 days later following the same time protocol, but without treatment. On both occasions, the sampling was started at 7.30 a.m. after an overnight fast and a standardized evening meal (at 7 p.m.) the day before. During lipid apheresis, total cholesterol was reduced by 50% from 294 to 148 mgadl. Thereby, low density lipoprotein cholesterol fell from 167 to 64 mgadl and lipoprotein (a) was reduced from 203 to 69 mgadl. Blood glucose concentration remained stable (4.95 mmolal baseline value, 5.05 mmolal at the end of treatment).
Serum leptin was found to be reduced from 67 ngaml at baseline to 39 ngaml after treatment (42% reduction, Figure 1 ). In the eluate a leptin concentration of 20 ngaml was found. Two days later circulating leptin concentration was 72 ngaml under baseline condition and showed only a slight decrease to 65 ngaml (10% reduction) after three hours without treatment ( Figure  1) , which corresponds to the diurnal leptin variation. Leptin reduction due to lipid apheresis by far exceeds the physiological diurnal variation.
Based on these data we suggest that in this patient during extracorporal cholesterol lowering therapy with Cascade¯o not only lipid particles were reduced but also circulating leptin concentrations. This suggestion is based on the ®ndings that (I) signi®cant amounts of leptin could be determined in the eluate and (II) the decline of plasma leptin concentration observed during treatment by far exceeds the physiological decline 3 and is in the range of reduction observed by a weight loss of about 10 kg body weight. 4 In human obesity increased concentrations of circulating leptin 4 are found, suggesting a possible resistance to leptin action. Fasting leptin concentration observed in our patient ®ts into the range observed for an amount of body fat as high as 35% of total body weight. Chronic renal failure has been reported to be accompanied by increased concentrations, 5 possibly explaining the high values in our patient.
No information exists on the effect of arti®cial reduction of serum leptin concentration on food intake and body weight. In our case elevated circulating baseline leptin concentrations were signi®cantly decreased by lipid apheresis. Energy intake on the day of treatment was signi®cantly higher than on days without treatment. This regular energy excess can explain the weight gain in our patient. Two days after treatment baseline leptin was slightly higher than the preapheresis value. This restoration of the patient's serum leptin concentration is possibly triggered by the excessive food intake.
Such a`relative' short-term hypoleptinaemia might play an important role in triggering food intake via disturbances in the leptin signalling pathway. Food intake and body weight, however, are determined by a complex interaction of regulatory hormones. Further evaluations are required to clarify the role of leptin and other satiety regulating hormones, which also might be disturbed by lipid apheresis. 
